Literature DB >> 29382774

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

David S Williams1,2, Dmitri Mouradov3,4, Robert N Jorissen3,4, Marsali R Newman1, Elham Amini5, David K Nickless6, Julie A Teague6, Catherine G Fang2, Michelle Palmieri3,4, Marie J Parsons4, Anuratha Sakthianandeswaren3,4, Shan Li4, Robyn L Ward7, Nicholas J Hawkins8, Ian Faragher9, Ian T Jones10, Peter Gibbs3,4,11,12, Oliver M Sieber3,4,13,14.   

Abstract

OBJECTIVE: Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic and transcriptomic subtypes remain unclear.
DESIGN: A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF/KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations with 5-year disease-free survival (DFS) were evaluated and validated in an independent cohort of 602 patients.
RESULTS: Tumours were categorised into four subtypes based on TIL and MMR status: TIL-low/proficient-MMR (pMMR) (61.3% of cases), TIL-high/pMMR (14.8%), TIL-low/dMMR (8.6%) and TIL-high/dMMR (15.2%). Compared with TIL-high/dMMR tumours with the most favourable prognosis, both TIL-low/dMMR (HR=3.53; 95% CI=1.88 to 6.64; Pmultivariate<0.001) and TIL-low/pMMR tumours (HR=2.67; 95% CI=1.47 to 4.84; Pmultivariate=0.001) showed poor DFS. Outcomes of patients with TIL-low/dMMR and TIL-low/pMMR tumours were similar. TIL-high/pMMR tumours showed intermediate survival rates. These findings were validated in an independent cohort. TIL/MMR status was a more significant predictor of prognosis than National Comprehensive Cancer Network high-risk features and was a superior predictor of prognosis compared with genomic (dMMR, pMMR/BRAFwt /KRASwt , pMMR/BRAFmut /KRASwt , pMMR/BRAFwt /KRASmut ) and transcriptomic (CMS 1-4) subtypes.
CONCLUSION: TIL/MMR classification identified subtypes of stage II/III colorectal cancer associated with different outcomes. Although dMMR status is generally considered a marker of good prognosis, we found this to be dependent on the presence of TILs. Prognostication based on TIL/MMR subtypes was superior compared with histopathological, genomic and transcriptomic subtypes. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  colorectal carcinoma; immune response; molecular pathology; tumour markers

Mesh:

Year:  2018        PMID: 29382774     DOI: 10.1136/gutjnl-2017-315664

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Is prognosis uniformly excellent in patients with stage II MSI-high colon cancer?

Authors:  Jane Wang; Georgios Antonios Margonis
Journal:  Ann Transl Med       Date:  2022-09

Review 2.  Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Authors:  David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz
Journal:  Curr Gastroenterol Rep       Date:  2019-01-30

3.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

4.  Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer.

Authors:  Martin R Weiser; Meier Hsu; Philip S Bauer; William C Chapman; Iván A González; Deyali Chatterjee; Deepak Lingam; Matthew G Mutch; Ajaratu Keshinro; Jinru Shia; Efsevia Vakiani; Tsuyoshi Konishi; Yoshifumi Shimada; Zsofia Stadler; Neil H Segal; Andrea Cercek; Leonard Saltz; Rona Yaeger; Anna Varghese; Maria Widmar; Iris H Wei; Emmanouil P Pappou; J Joshua Smith; Garrett Nash; Philip Paty; Julio Garcia-Aguilar; Mithat Gonen
Journal:  J Clin Oncol       Date:  2021-01-13       Impact factor: 44.544

5.  Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.

Authors:  Jerzy Lasota; Małgorzata Chłopek; Jennifer Lamoureux; Jason Christiansen; Artur Kowalik; Bartosz Wasąg; Anna Felisiak-Gołąbek; Abbas Agaimy; Wojciech Biernat; Vincenzo Canzonieri; Giovanni Centonze; Ewa Chmielik; Ondrej Daum; Magdalena Dubová; Ireneusz Dziuba; Sebastian Goertz; Stanisław Góźdź; Anna Guttmejer-Nasierowska; Caj Haglund; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Paweł Kita; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Ari Ristimäki; Janusz Ryś; Blażej Szostak; Joanna Szpor; Justyna Szumiło; Leszek Teresiński; Piotr Waloszczyk; Jarosław Wejman; Wojciech Wesołowski; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2020-02       Impact factor: 6.298

6.  Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.

Authors:  Sara Lonardi; Matteo Fassan; Fotios Loupakis; Ilaria Depetris; Paola Biason; Rossana Intini; Alessandra Anna Prete; Francesco Leone; Pasquale Lombardi; Roberto Filippi; Andrea Spallanzani; Stefano Cascinu; Luca Reggiani Bonetti; Giulia Maddalena; Nicola Valeri; Andrea Sottoriva; Luis Zapata; Roberta Salmaso; Giada Munari; Massimo Rugge; Angelo Paolo Dei Tos; Justin Golovato; John Z Sanborn; Andrew Nguyen; Marta Schirripa; Vittorina Zagonel
Journal:  Oncologist       Date:  2020-01-22       Impact factor: 5.837

Review 7.  Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.

Authors:  Jerzy Lasota; Małgorzata Chłopek; Bartosz Wasąg; Artur Kowalik; Jason Christiansen; Jennifer Lamoureux; Alina Kuźniacka; Anna Felisiak-Gołąbek; Yalan Liu; Tiffany Ashley R Reyes; Rishabh Saha; Abbas Agaimy; Kristyna Behenska; Wojciech Biernat; Laura Cattaneo; Giovanni Centonze; Ondrej Daum; Magdalena Daumova; Paweł Domagała; Ireneusz Dziuba; Carol E Geppert; Stanisław Góźdź; Anna Nasierowska-Guttmejer; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Janusz Ryś; Piotr Waloszczyk; Jaroslaw Wejman; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2020-09       Impact factor: 6.298

8.  Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.

Authors:  Douglas J Hartman; Madison Frank; Lindsey Seigh; Haroon Choudry; James Pingpank; Matthew Holtzman; David Bartlett; Nathan Bahary; Liron Pantanowitz; Reetesh K Pai
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.298

Review 9.  Perspective: cancer vaccines in the era of immune checkpoint blockade.

Authors:  Jonathan Cebon
Journal:  Mamm Genome       Date:  2018-11-16       Impact factor: 2.957

10.  Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Sanne Ten Hoorn; Tim R de Back; Dirkje W Sommeijer; Louis Vermeulen
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.